Tubulis, a Munich, Germany-based generator of matched protein-drug conjugates, raised 60M in Series B funding.
The round was led by Andera Partners with participation from Evotec, Fund+, Bayern Kapital, BioMedPartners, coparion, High-Tech Gründerfonds, Occident and Seventure Partners. In conjunction with the round, Sofia Ioannidou, PhD, Partner at Andera Partners, Thomas Hanke, PhD, EVP, Head of Academic Partnerships at Evotec as well as Jan Van den Bossche, Partner at Fund+ will join Tubulis’ Board of Directors consisting of Sebastian Pünzeler, PhD, Principal at coparion, Dominik Schumacher, PhD, CEO of Tubulis and Christian Grøndahl, MD, DVM, PhD, MBA, the Chairman of the Board. In addition, Valentin Piëch, PhD, Partner at BioMedPartners will take over the board seat from Michael Wacker, PhD, General Partner at BioMedPartners.
The company intends to use the funds to advance its proprietary pipeline of uniquely assembled antibody drug conjugates (ADCs), towards clinical evaluation as well as introduce programs addressing a range of solid tumor indications.
Led by Dominik Schumacher, CEO, Tubulis generates matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Its capability of creating a pipeline of antibody-drug conjugates is based on a diverse range of targeting molecules, novel payloads and proprietary conjugation technologies. They enable the discovery of innovative ADCs that can increase antibody conjugation options via novel chemical groups leading to stable, high drug-to-antibody ratios.
The company’s lead tumor-targeting assets are currently in preclinical development addressing several high unmet medical need indications. Tubulis’ pipeline also includes a program for hematological tumors, which is on the path towards IND-readiness.